Neurokinin antagonists and their potential role in treating depression and other stress disorders

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 10, 2004, Pages 1421-1433

  Albert, Jeffrey S ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Depression; Neurokinin; NK1; NK2; NK3; Psychosis; Schizophrenia; Tachykinin

Indexed keywords

AMINOPYRIDINE DERIVATIVE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CANNABINOID RECEPTOR ANTAGONIST; CYCLOBUTANE; CYCLOLEUCINE; EPLIVANSERIN; FLUOXETINE; ISOQUINOLINE DERIVATIVE; L 759274; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; OSANETANT; PHENYLALANINE DERIVATIVE; PIPERIDINE DERIVATIVE; PIPERIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; R 673; SAREDUTANT; SR 48962; TACHYKININ RECEPTOR ANTAGONIST; TAK 637; TALNETANT; TETRAHYDROPYRAN DERIVATIVE; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOFOPITANT;

ANXIETY DISORDER; BINDING AFFINITY; BODY WEIGHT DISORDER; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEPRESSION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL DISEASE; HUMAN; MEDICAL LITERATURE; METABOLIC DISORDER; NEUROCHEMISTRY; NONHUMAN; PATENT; PSYCHOSIS; REVIEW; SEXUAL DYSFUNCTION; STRUCTURE ACTIVITY RELATION; VOMITING; WEIGHT GAIN;

EID: 5744220634     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.10.1421     Document Type: Review

References (35)

1. HOLMES A, HEILIG M, RUPNIAK NM, STECKLER T, GRIEBEL G: Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharm. Sci. (2003) 24:580-588.
2. DATAR P, SRIVASTAVA S, COUTINHO E, GOVIL G: Substance P: structure, function, and therapeutics. Curr. Top. Med. Chem. (2004) 4:75-103.
3. GIARDINA GA, GAGLIARDI S, MARTINELLI M: Antagonists at the neurokinin receptors - recent patent literature. IDrugs (2003) 6 758-772.
4. JOHANSSON A: Recent developments in the medicinal chemistry of NK2 receptor antagonists. Curr. Top. Med. Chem. (2003) 3 1436-1445.
5. HUMPHREY JM: Medicinal chemistry of selective neurokinin-1 antagonists. Curr. Top. Med. Chem. (2003) 3:1423-1435.
6. KEHNE JH, MAYNARD GD, DE LOMBAERT S, KRAUSE JE: Neuropeptide receptor antagonists for CNS disorders. Ann. Rep. Med. Chem. (2003) 38:11-20.
7. PACHER P, KECSKEMETI V: Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr. Med. Chem. (2004) 11:925-943.
8. RUPNIAK NM: Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr. Opin. Invest. Drugs (2002) 3:257-261.
9. ADELL A: Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms? Current Drug Targets: CNS & Neurological Disorders (2004) 3:113-121.
10. TOONEY PA, AU GG, CHAHL LA: Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain. Clin. Exp. Pharmacol. Physiol. (2000) 27:947-949.
11. MILEUSNIC D, MAGNUSON DJ, HEJNA MJ et al.: Age and species-dependent differences in the neurokinin B system in rat and human brain. Neurobiol. Aging (1999) 20:19-35.
12. KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281:1640-1645.
13. BERGSTROM M, HARGREAVES RJ, BURNS HD et al.: Human positron emission tomography studies of brain neurokinin-1 receptor occupancy by aprepitant. Biol. Psych. (2004) 55:1007-1012.
14. KRAMER MS, WINOKUR A, KELSEY J et al.: Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropschopharmacology (2004) 29 385-392.
15. HOFFMANN T, BALLARD T, BOS M et al.: Annual meeting on frontiers in medicinal chemistry, Erlangen, Germany, 15-17 March (2004).
16. STEVENSON GI, HUSCROFT I, MACLEOD AM et al.: 4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity. J. Med. Chem. (1998) 41:4623-4635.
17. OKANO S, IKEURA Y, INATOMI N: Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J. Pharmacol. Exp. Ther. (2002) 300 925-931.
18. NATSUGARI H, IKEURA Y, KAMO I et al.: Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK1 receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions. J. Med. Chem. (1999) 42:3982-3993.
19. ISHICHI Y, IKEURA Y, NATSUGARI H: Amide-based atropisomers in tachykinin NK1-receptor antagonists: synthesis and antagonistic activity of axially chiral N-benzylcarboxamide derivatives of 2,3,4,5-tetrahydro-6H-pyrido[2,3-b] [1,5]oxazocin-6-one. Tetr. (2004) 60:4481-4490.
20. POULSEN A, BJORNHOLM B, GUNDERTOFTE K, POGOZHEVA ID, LILJEFORS T: Pharmacophore and receptor models for neurokinin receptors. J. Comp. Aided Mol. Des. (2004) 17:765-783.
21. CAPPELLI A, GIULIANI G, PERICOT GM et al.: A non-peptide NK1 receptor agonist showing subpicomolar affinity. J. Med. Chem. (2004) 47:1315-1318.
22. ALBERT JS, OHNMACHT C, BERNSTEIN PR et al.: Design and optimization of cyclized NK1 antagonists with controlled atropisomeric properties. Tetr. (2004) 60:4337-4347.
23. ALBERT JS, AHARONY D, ANDISIK D et al.: Design, synthesis, and SAR of tachykinin antagonists: modulation of balance in NK1/NK2 receptor antagonist activity. J. Med. Chem. (2002) 45 3972-3983.
24. BENSAID M, FAUCHEUX BA, HIRSCH E et al.: Expression of tachykinin NK2 receptor mRNA in human brain. Neurosci. Lett. (2001) 303:25-28.
25. SAFFROY M, TORRENS Y, GLOWINSKI J, BEAUJOUAN JC: Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience (2003) 116:761-773.
26. STEINBERG R, ALONSO R, GRIEBEL G et al.: Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J. Pharmacol. Exp. Ther. (2001) 299:449-458.
27. DESVIGNES C, ROUQUIER L, SOUILHAC J et al.: Control by tachykinin NK2 receptors of CRF1 receptor-mediated activation of hippocampal acetylcholine release in the rat and guinea-pig. Neuropeptides (2003) 37:89-97.
28. SANOFI-SYNTHELABO: Press release. 16 February (2004).
29. MELTZER HY, ARVANITIS L, BAUER D, REIN W: Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry (2004) 161 975-984.
30. EMONDS-ALT X, PROIETTO V, STEINBERG R et al.: Biochemical and pharmacological activities of SSR-146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can. J. Phy. Pharmacol. (2002) 80:482-488.
31. GLAXOSMITHKLINE: Analyst presentation, London. 3 December (2003).
32. RYCKMANS T, BERTON O, GRIMEE R et al.: Dual NK1 antagonists-serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives. Bioorg. Med. Chem. Lett. (2002) 12:3195-3198.
33. GENICOT C, CHRISTOPHE B, COLLART P et al.: Discovery of orally bioavailable NK1 receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:437-442.
34. GUIARD BP, PRZYBYLSKI C, GUILLOUX J-P et al.: Blockade of substance P (neurokinin-1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo rnicrodialysis study in mice. J. Neurochem. (2004) 89 54-63.
35. HENSLEY S, LANDERS P. Wall Street Journal 24 Feb. (2004).